Recording and classifying MET receptor mutations in cancers.

Abstract excerpt

Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This success is the consequence of a long characterization of MET mutations in cancers, which we propose to outline in this review. MET, a receptor tyrosine kinase (RTK), displays in a broad panel of cancers many deregulations liable to promote...

Topics

Join the communities discussing this publication.

• Mutation
• Neoplasms
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins c-met